Patent 10166190
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Active provider: Google · gemini-2.5-flash
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
Current assignee: Veloxis Pharmaceuticals AS
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Proceedings overview
There are no AIA trial proceedings on file for US patent 10166190 as of the most recent ingest of USPTO Open Data Portal information, and web search did not surface any additional proceedings. This means the patent's claims remain untested by an AIA trial at the PTAB, offering a defendant maximum flexibility in challenging the patent.
Strategic summary
As of today, US patent 10166190 has no PTAB activity on file. All claims of the patent are currently UNTESTED in an AIA trial setting. This means that a potential defendant facing assertion of this patent would have the full range of prior-art grounds available under §§ 102 and 103 for an Inter Partes Review (IPR), or broader grounds for a Post-Grant Review (PGR) if applicable, without facing any estoppel bars under § 315(e)(2). The absence of PTAB challenges for a patent of this age (published January 1, 2019, with priority to 2008-05-30) could indicate a lack of assertion or that prior challenges were resolved privately.
Recommended next steps
Since no PTAB activity exists for US10166190, a defendant facing assertion would have a clear path to file an IPR petition without concern for estoppel from previous PTAB trials. The absence of previous challenges means the patent has not been "hardened" by surviving IPRs, and all available prior art and statutory grounds are open for challenge.
Generated 5/31/2026, 12:49:15 AM